AXGN vs. EDAP, ZYXI, VRAY, FONR, BSGM, ELMD, HYPR, BLFS, OM, and BLUE
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Zynex (ZYXI), ViewRay (VRAY), FONAR (FONR), BioSig Technologies (BSGM), Electromed (ELMD), Hyperfine (HYPR), BioLife Solutions (BLFS), Outset Medical (OM), and bluebird bio (BLUE). These companies are all part of the "medical" sector.
AxoGen vs.
Edap Tms (NASDAQ:EDAP) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.
Edap Tms has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Edap Tms presently has a consensus price target of $13.75, suggesting a potential upside of 36.00%. AxoGen has a consensus price target of $17.00, suggesting a potential upside of 91.23%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Edap Tms.
48.8% of Edap Tms shares are owned by institutional investors. Comparatively, 76.2% of AxoGen shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by insiders. Comparatively, 7.5% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
AxoGen has a net margin of -17.01% compared to Edap Tms' net margin of -19.22%. AxoGen's return on equity of -15.23% beat Edap Tms' return on equity.
AxoGen received 92 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.77% of users gave AxoGen an outperform vote while only 63.50% of users gave Edap Tms an outperform vote.
In the previous week, Edap Tms had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Edap Tms and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.15 beat Edap Tms' score of 0.62 indicating that AxoGen is being referred to more favorably in the news media.
Edap Tms has higher earnings, but lower revenue than AxoGen. Edap Tms is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.
Summary
AxoGen beats Edap Tms on 12 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools